BridgeBio Pharma Inc’s recently made public that its Chief Executive Officer Kumar Neil unloaded Company’s shares for reported $2.19 million on Oct 09 ’25. In the deal valued at $54.80 per share,40,000 shares were sold. As a result of this transaction, Kumar Neil now holds 835,686 shares worth roughly $46.37 million.
Then, Kumar Neil sold 40,000 shares, generating $2,191,350 in total proceeds. Upon selling the shares at $54.78, the Chief Executive Officer now owns 855,686 shares.
Before that, KUMAR HALDEA FAMILY IRREVOCABL bought 120,000 shares. BridgeBio Pharma Inc shares valued at $6,506,400 were divested by the Director at a price of $54.22 per share.
A number of analysts have revised their coverage, including Truist’s analysts, who began to cover the stock in late July with a ‘”a Buy”‘ rating. Jefferies began covering BBIO with “Buy” recommendation on July 14, 2025. Oppenheimer revised its rating on July 09, 2025. It rated BBIO as “an Outperform” which previously was an “a Perform”.
Price Performance Review of BBIO
On Friday, BridgeBio Pharma Inc [NASDAQ:BBIO] saw its stock jump 1.28% to $55.49. Over the last five days, the stock has gained 4.98%. BridgeBio Pharma Inc shares have risen nearly 124.38% since the year began. Nevertheless, the stocks have risen 102.22% over the past one year.
How much short interest is there in BridgeBio Pharma Inc?
A steep rise in short interest was recorded in BridgeBio Pharma Inc stocks on 2025-09-30, dropping by -2.42 million shares to a total of 17.49 million shares. Yahoo Finance data shows the prior-month short interest on 2025-08-29 was 19.91 million shares. There was a decline of -13.86%, which implies that there is a negative sentiment for the stock.
The most recent change occurred on June 17, 2025 when Wolfe Research began covering the stock and recommended ‘”an Outperform”‘ rating along with a $49 price target.
